Skip to main content
49°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mei Pharma Inc
(NQ:
MEIP
)
3.060
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mei Pharma Inc
< Previous
1
2
3
4
Next >
MEI Pharma Responds to Anson and Cable Car
June 27, 2023
From
MEI Pharma, Inc.
Via
Business Wire
Anson Funds and Cable Car Capital Issue Statement Regarding the Inferior Proposed Transaction between MEI Pharma and Infinity Pharmaceuticals
June 27, 2023
From
Anson Funds Management LP
Via
GlobeNewswire
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
June 15, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor
June 13, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor
June 02, 2023
From
MEI Pharma, Inc.
Via
Business Wire
Anson Funds and Cable Car Capital Issue Statement Regarding MEI Pharma’s Rejection of Their Acquisition Proposal
June 01, 2023
From
Anson Funds Management LP
Via
GlobeNewswire
MEI Pharma Board of Directors Rejects Unsolicited Proposal
June 01, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal
May 30, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies
May 23, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational Highlights
May 11, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces 1-for-20 Reverse Stock Split
April 14, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEIP STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of MEI Pharma, Inc. Is Fair to Shareholders
February 23, 2023
From
Halper Sadeh LLC
Via
Business Wire
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates
February 23, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reports Second Quarter Fiscal Year 2023 Results and Operational Highlights
February 09, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Adjournment of Annual Meeting of Stockholders
December 06, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Initiates Strategic Realignment
December 05, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
December 05, 2022
From
MEI Pharma, Inc.
Via
Business Wire
Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan
November 18, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reports First Quarter Fiscal Year 2023 Results and Operational Highlights
November 14, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022
November 03, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Changes to Board of Directors
September 22, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reports Fiscal Year 2022 Results and Operational Highlights
September 08, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022
September 06, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
September 01, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma to Release 2022 Fiscal Year End Financial Results and Provide Corporate Update on September 8, 2022
September 01, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
August 01, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy
July 18, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer
June 22, 2022
From
MEI Pharma, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.